Companies › HRYZ Biotech
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MASCT-I Dendritic cell and effector T cell therapy | – | Phase 2 | Leiomyosarcoma | Feb 2027 |
| HRYZ-T101 Injection HPV18-specific TCR-engineered T cells | – | Phase 1 | Cervical Cancer | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06277154 | MASCT-I | Phase 2 | Leiomyosarcoma | Oncology | Feb 2027 |
| NCT05952947 | HRYZ-T101 Injection | Phase 1 | Cervical Cancer | Oncology | Dec 2027 |
No annotated target.
–
Diakonos Oncology iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.